HALB (Halberd) Other Current Payables: $0.19 Mil (As of Jul. 2023)


What is Halberd Other Current Payables?

Halberd HALB -1.05% Other Current Payables is $0.19 Mil as of Jul. 2023.

Halberd's Other Current Payables for the quarter that ended in Jul. 2023 was $0.19 Mil.

Halberd's quarterly Other Current Payables increased from Jul. 2008 ($0.03 Mil) to Jul. 2022 ($0.21 Mil) but then declined from Jul. 2022 ($0.21 Mil) to Jul. 2023 ($0.19 Mil).

Halberd's annual Other Current Payables increased from Jul. 2008 ($0.03 Mil) to Jul. 2022 ($0.21 Mil) but then declined from Jul. 2022 ($0.21 Mil) to Jul. 2023 ($0.19 Mil).

Halberd Other Current Payables Related Terms

Halberd Other Current Payables Historical Data

* Premium members only.

The historical data trend for Halberd's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Halberd Other Current Payables Chart

Halberd Annual Data
Trend Jul08 Jul22 Jul23
Other Current Payables
0.03 0.21 0.19

Halberd Semi-Annual Data
Jul08 Jul22 Jul23
Other Current Payables 0.03 0.21 0.19

Halberd Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of $0.19 Mil mean?
Halberd (HALB) has a Other Current Payables of $0.19 Mil as of Jul. 2023. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Halberd and its competitors.
Is Halberd's Other Current Payables too high?
Halberd's current Other Current Payables is $0.19 Mil.
How does Halberd's Other Current Payables compare to GRI and OCEA?
Halberd's Other Current Payables of $0.19 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Halberd and its competitors. Halberd's current Other Current Payables is $0.19 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halberd stock overvalued right now?
Halberd (HALB) has a current Other Current Payables of $0.19 Mil. The current Other Current Payables is $0.19 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Halberd (HALB), the current Other Current Payables is $0.19 Mil as of Jul. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Halberd Business Description

Address P.O. Box 25, Jackson Center, PA, USA, 16133
Halberd Corp is a holding company and acquisition vehicle for established businesses. It is also developing a patented process for disease eradication by removing the pathophysiologic basis of the disease. The company is focused on developing treatments for neurodegenerative diseases, such as PTSD and CTE (Post Traumatic Stress Disorder and Chronic Traumatic Encephalopathy), Alzheimer's Disease, Parkinson's Disease, etc.